T ype 1 diabetes (T1D)
3 is a T cell-mediated organ-specific autoimmune disease that results from selective destruction of the ␤ cells in the islets of the pancreas (1) . T cells specific for a number of islet Ags can be detected in humans and nonobese diabetic (NOD) mice (2) . Initiation of autoimmunity in NOD mice may be dependent on an immune response against insulin alone rather than an immune response against many ␤ cell Ags. We and others have independently shown that transgenic overexpression of proinsulin 2 in APCs of NOD mice prevents insulitis and diabetes (3, 4) . Knocking out both insulin genes and introduction of mutated insulin with alanine rather than tyrosine at position 16 of the insulin B chain prevents insulitis and diabetes (5) . Eliminating immune responses to insulin not only blocks development of diabetes and insulitis but also immune responses to downstream autoantigens, such as the islet-specific glucose-6-phosphatase catalytic subunit related protein (IGRP) (6) . In both humans and animal models, the major determinants of T1D are genes within the MHC [HLA in humans] (7). The remarkable homogeneity of high-risk genotypes across different populations and the conservation of aspects of the Ag-binding groove suggest that there may be specific peptides that for most individuals represent the initiating targets of autoimmunity (8) . In NOD mice (and probably also in humans), the primary autoantigen for diabetes appears to be insulin, specifically the insulin B chain peptide B9-23 (5) .
Identification of target autoantigens for T cells is particularly important because manipulation of immune responses to these Ags offers the hope of specifically removing the cells that damage ␤ cells. We and others have proposed that autoreactivity to insulin is necessary and precedes autoreactivity to IGRP and other autoantigens (3, 5, 6) . If insulin is the primary Ag, a strategy that induces tolerance to insulin should prevent diabetes. Although this prevented diabetes in NOD mice (9) , major preventive trials with either oral or i.v. insulin have thus far failed to prevent diabetes in humans (10 -12) . Human subjects enrolled in prevention trials have multiple autoantibodies, suggesting advanced preclinical diabetes. By the time the intervention occurs, tissue inflammation has already developed, the immune response has already expanded beyond the initial "triggering" Ag, and the frequency of diverse array of Ag-specific T cells may have expanded substantially. Therefore, a clinically important question is whether induction of tolerance to the primary Ag will be effective when there is already an expanded pool of Ag-specific T cells. We wished to know whether inducing tolerance to insulin would have any effect in NOD mice that already have an expanded number of T cells specific for IGRP. To address this question, we crossed TCR transgenic mice that have Ͼ90% of their CD8 ϩ T cells specific for IGRP 206 -214 (NOD8.3 mice) (13) with NOD mice tolerant to proinsulin (NOD-PI mice) that express proinsulin 2 in APCs, making them tolerant to proinsulin (3). These mice have dramatically reduced diabetes, indicating that the requirement for immunity to proinsulin is even present in the majority of NOD8.3 mice with a pre-existing repertoire of IGRP 206 -214 -specific cells.
Materials and Methods
Mice NOD mice expressing mouse proinsulin 2 under the control of an MHC class II (I-E␣) promoter (NOD-PI) and NOD8.3 mice expressing the TCR␣␤ rearrangements of the H-2K
d -restricted CD8 ϩ T cell clone NY8.3 have been described (3, 5, 6) . Perforin knockout NOD mice were obtained from The Jackson Laboratory T1D repository. All animal studies were conducted at St. Vincent's Institute (Melbourne, Australia) and were approved by the institutional animal ethics committee.
Peptides and Abs
The peptides IGRP 206 -214 
In vitro T cell proliferation assay

MHC class I staining
Islets of Langerhans were isolated from mice according to methods previously described (14) . For MHC class I staining, antisera used were antimouse H-2D b (28 -14-8; BD Pharmingen) followed by allophycocyaninconjugated streptavidin (Caltag Laboratories). Leukocytes were excluded from analysis by staining with anti-CD45 conjugated to PerCp-Cy5.5 (3F11; BD Pharmingen), and ␤ cells were identified based on their high autofluorescence (14) .
Anti-CD4 Ab treatment
Five 7-wk-old NOD-PI/NOD8.3 mice were injected with anti-CD4 mAb (GK1.5) or isotype control (GL121). The dose was 1 mg followed by 0.5 mg after 3 days. Thereafter 0.5 mg was injected every week until the mouse became diabetic or for 8 wk. Mice were monitored for success of depletion using noncompeting anti-CD4 (clone RM4-4; BD Pharmingen).
Histological analysis
Immunohistochemical staining and scoring of frozen pancreas sections was performed as described (15, 16) . Mice were monitored for diabetes as described (6) .
Insulin autoantibody assay (IAA)
IAA were measured with a 96-well filtration plate micro IAA assay as described. (6) We have participated in all the Diabetes Autoantibody Standardization Program workshops. In the murine IAA workshop (2002), the sensitivity and specificity for IAA were 69 and 83%, respectively.
Statistics
Insulin autoantibody levels and insulitis scores were analyzed by Student's t test. Survival curves were analyzed with the log-rank test. Statistical tests used PRISM software (version 3.02; GraphPad). Values of p Ͻ 0.05 was considered significant.
Results
NOD-PI/NOD8.3 mice are protected from diabetes
We have shown that tolerance to proinsulin prevents expansion of IGRP 206 -214 -specific T cells (6) . To study the effect of tolerance to insulin on an expanded pool of autoreactive T cells, we crossed NOD8.3 TCR transgenic mice to NOD-PI mice.
The proportions of CD4 ϩ or CD8 ϩ T cells in NOD-PI/NOD8.3 mice were similar to NOD8.3 mice, and there was no difference in numbers of IGRP 206 -214 -specific T cells, suggesting normal development of CD8 ϩ T cells in NOD-PI/NOD8.3 mice (Fig. 1, A  and B) . IGRP 206 -214 -specific naive T cells from the spleens of NOD-PI/NOD8.3 mice proliferated in response to the peptide both in vitro and in vivo similarly to IGRP 206 -214 -specific T cells from NOD8.3 mice (Fig. 1, C and D) . Moreover, IGRP 206 -214 -specific splenic T cells from NOD-PI/NOD8.3 and NOD8.3 mice secreted IFN-␥ in response to the peptide to a similar extent, and splenocytes from these mice transfer diabetes into irradiated NOD mice to a similar extent, suggesting normal cytotoxic potential (Fig. 1,  E and F) .
Despite normal number and function of IGRP 206 -214 -specific T cells, NOD-PI/NOD8.3 mice have reduced insulitis and are markedly protected from diabetes (Fig. 2, A and B) . Most of the CD8 ϩ T cells infiltrating islets of NOD-PI/NOD8.3 mice are specific for IGRP (Fig.  2E) . The important difference between NOD-PI/NOD8.3 mice and NOD8.3 mice is the ability to mount an immune response against insulin. A total of 40% of female NOD8.3 mice (4/10) had high titer IAA, whereas only 9.4% NOD-PI/NOD8.3 mice (3/32) had a borderline positive IAA (Fig. 2C) . Recently, it has been shown that insulin primed CD4 immune responses for their full activation and ability to mediate ␤ cell destruction.
Dominant tolerance does not account for protection from diabetes in NOD-PI/NOD8.3 mice
Regulatory T cells (Tregs) could account for diabetes protection in NOD-PI/NOD8.3 mice but we previously did not find evidence for this mechanism in NOD-PI mice (6). Also, there was no difference in number of FoxP3 ϩ CD4 ϩ T cells between NOD and NOD-PI mice and between NOD8.3 and NOD-PI/NOD8.3 mice (Fig. 3A) . However, Tregs could have different suppressive potential. No difference in suppressive activity of CD4 ϩ CD25 ϩ from NOD or NOD-PI mice on proliferation of IGRP-specific CD8 ϩ T cell was observed in vivo or in vitro (Fig. 3, B and C) . Moreover, IGRP 206 -214 -specific T cells from NOD-PI/NOD8.3 mice had similar proliferative and IFN-␥ responses to IGRP 206 -214 compared with cells from NOD8.3 mice (Fig. 1, C-E (Fig. 3, D and E) .
Stimulating Ag presentation bypasses tolerance to proinsulin leading to proliferation of IGRP-specific T cells and diabetes
It is surprising that despite being present in such a large number, IGRP-specific T cells are tolerant to IGRP in the absence of immune responses to insulin. IGRP 206 -214 -specific T cells remain ignorant of their Ag in NOD-PI hosts (6). We therefore reasoned that IGRP 206 -214 -specific T cells, despite being present in large numbers, might remain ignorant of their Ag, meaning that tolerance should be broken by increasing T cell activation signals. Indeed, FACS analysis of ␤ cells from NOD-PI/NOD8.3 mice showed decreased MHC class I expression, which could reduce their targeting by CD8 ϩ T cells (Fig. 2D ). We questioned whether decreased cross-priming of IGRP 206 -214 -specific T cells in NOD-PI hosts could be overcome in response to ␤ cell death or islet inflammation. In the absence of infection, DC maturation occurs following uptake of Ags from apoptotic cells or by ligation of CD40 by CD154 on CD4 ϩ T cells (18 -21) . We assessed proliferation of transferred IGRP 206 -214 -specific T cells following CD40 agonist Ab treatment or induction of ␤ cell apoptosis by low dose STZ. A single dose of 80 mg/kg of STZ or 100 g of CD40 agonist Ab was used based on published reports (22) (23) (24) . Each of these increased proliferation of NOD8.3 T cells (Fig. 4, A-C) .
In addition, we also analyzed IGRP 206 -214 -specific T cells transferred into perforin knockout NOD mice (NOD perforin Ϫ/Ϫ ). These mice have insulitis but very little ␤ cell destruction and reduced and delayed diabetes development (25) . Transferred IGRP 206 -214 -specific T cells proliferated to a similar extent as in NOD mice (Fig. 4D) , indicating that the reduced ␤ cell destruction in these mice does not decrease Ag presentation. Together, these experiments suggested that protection by induction of tolerance to proinsulin could be bypassed.
We next examined whether breaking tolerance by STZ or CD40 Ab treatment in NOD-PI/NOD8.3 could induce diabetes. Administration of a single dose of STZ or CD40 Ab treatment increased MHC class I expression on ␤ cells within 3 days (Fig. 5A) and resulted in diabetes within 1-4 wk in NOD-PI/NOD8.3 mice (Fig.  5, C and D) . The islet infiltrating cells were predominantly IGRP 206 -214 CD8 ϩ cells in these mice (Fig. 5B) . This suggests that even with many Ag-specific T cells, immune responses to insulin are required for full diabetes development. However, this requirement can be bypassed by stimuli that induce ␤ cell apoptosis or promote inflammation. In contrast, this treatment had no effect on the incidence of diabetes in NOD or NOD-PI mice indicating (a) the treatment is stimulating T cells to mediate diabetes and not directly inducing ␤ cell death and (b) mere stimulation of ␤ cell apoptosis or promotion of islet inflammation is not sufficient, without a large number of Ag-specific T cells.
Discussion
This study showed that immune responses against proinsulin, that could be eliminated by expression of proinsulin in APCs, are required in the majority of NOD8.3 TCR transgenic mice for their IGRP-specific T cells to become activated and kill ␤ cells. Diabetes was reduced from nearly 100 to 20%, indicating that little T cell activation and progression occurred in mice with proinsulin immune tolerance (confirmed by absent IAA). That an immune response to one Ag is required for an effective immune response by TCR transgenic T cells specific for a different Ag has not previously been reported. However, aspects of previous studies are consistent with the current finding. Some previous CD8 ϩ TCR transgenic mice specific for certain Ags that have been transgenically expressed in the ␤ cell have not shown immune reactivity against that Ag (26) . An activation step is required, either infection with virus, for example LCMV when LCMV glycoprotein is expressed in ␤ cells (26) , or cotransfer of Ag-specific CD4 ϩ T cells when a model pathogen or nonpathogen-derived Ag, such as influenza hemagglutinin or OVA, is expressed in ␤ cells (27, 28) . Therefore exposure to pathogens with activation of the innate immune system or "help" from CD4 ϩ T cells can promote progression to diabetes. Further, it was already known that NOD8.3 CD8 ϩ T cells need CD4 ϩ "help" for activation since NOD8.3 mice on a recombination activating genes knock out (Rag Ϫ/Ϫ ) background also reduced frequency of diabetes (13) . NOD8.3 mice have high titer IAA, indicating that the mice can generate immune responses against islet Ags other than IGRP despite their biased repertoire. Lastly, we previously showed that IGRP responses in nontransgenic NOD mice are dependent on responses to proinsulin (6) .
In contrast to NOD-PI mice, the protection from diabetes is not complete in NOD-PI/NOD8.3 mice. Approximately 20% of the mice develop delayed diabetes. Reduced and delayed diabetes also occurs in NOD8.3 mice on Rag Ϫ/Ϫ background, in which insulinspecific T cells are not expected to be present (13) . Because of the unnaturally high frequency of ␤ cell-specific T cells in NOD8.3 mice, some may undergo activation without insulin-specific T cells either in response to cross-reactive Ags or IGRP occasionally shed from ␤ cells and presented in the pancreatic lymph node even in the absence of any autoimmune-mediated ␤ cell damage (13) .
The current study shows that requirements for T cell help, suggested by artificial transgenic models of diabetes, apply also to NOD8.3 mice with T cells that recognize IGRP, a natural ␤ cell Ag and, in the NOD mouse, a spontaneous model of diabetes. Surprisingly, it appears that this help can come from T cells specific for proinsulin, spontaneously generated as a result of the NOD MHC and other NOD genes, rather than a more general requirement for CD4 ϩ T cells of broad specificity. Although there is evidence that induction of tolerance to insulin can induce dominant tolerance to other Ags (29) , to our knowledge, this is the first study to show recessive tolerance to insulin can induce tolerance to other Ags in a TCR transgenic mouse. We could reproduce the effect of insulin-specific T cells in vivo by activating APCs with agonistic anti-CD40 Ab or by STZ-induced ␤ cell apoptosis, that may act through TLR-2 (30). Therefore, IGRP-specific CD8 ϩ T cells, even when present in large numbers, need an insulin-specific response, or something to replace it, to become fully active effector T cells and cause diabetes.
There may be significant clinical implications for this study. Subjects with preclinical diabetes enrolled in autoantigen intervention studies usually have responses to several autoantigens, indicating existing expanded T and B cell autoreactive populations. Our study suggests that depletion of proinsulin (primary autoantigen)-specific T cells may have a beneficial effect on other autoreactive T cells despite their prior expansion. There may be indirect evidence in humans for this. There was a significant effect of oral insulin in individuals who began the DPT-1 trial with high levels of insulin autoantibodies, indicating insulin autoimmunity. Tolerance induction with proinsulin in such subjects might, however, be bypassed if stimuli that enhance Ag presentation occur. Expansion of Ag-specific T cells in NOD8.3 mice is a result of expression of the TCR transgene in T cell precursors and thymic positive selection and is independent of T cell help. This has allowed us to show that NOD8.3 T cells need T cell help for effector function independent of proliferation. In a nontransgenic T cell repertoire, expansion and activation of Ag-specific T cells are not separated in this way. The current study suggests there might be beneficial effects of terminating insulin-specific CD4 ϩ T cell help in NOD mice or humans with established preclinical diabetes and autoimmunity to multiple ␤ cell Ags.
